Prior to these recent clinical trial results, I was optimistic that MariTide could make Amgen an underrated stock to own. Patients having just a monthly injection which might yield similar weight ...

New GLP-1 weight-loss pills from Novo Nordisk and Eli Lilly are likely to boost consumer demand, but employer-sponsored ...

Sales of GLP-1 drugs Mounjaro and Zepbound disappointed investors.Shelby Knowles/Bloomberg News Eli Lilly had a bad quarter, with sales of GLP-1 drugs Mounjaro and Zepbound missing analyst estimates.

To be clear, orforglipron didn't flop in its late-stage study. The company said that all three doses of the experimental drug met the primary end point of the trial as well as all key secondary end ...

Lilly pill led to 12%-15% reduction in body weight in clinical trials Will be sold as Foundayo and available beginning April 6 FDA fast-tracked approval under Trump-era voucher program The Lilly drug, ...